|
GSK Signs
Drug Development Deal With Regulus
April 17, 2008—Pharmaceutical giant GlaxoSmithKline inked a deal
with Carlsbad-based Regulus Therapeutics LLC valued at up to
$600 million to develop new microRNA drugs that target
inflammatory disease, the companies said April 17. Under the
agreement, Regulus will be responsible for developing microRNA
drugs targeted at inflammatory diseases such as rheumatoid
arthritis and inflammatory bowel disease; GlaxoSmithKline will
have the option to license prospective products.
San Diego Business Journal
|
